These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

707 related items for PubMed ID: 16757355

  • 1. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 3. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 15; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 4. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 15; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 5. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S.
    Circulation; 2008 Nov 11; 118(20):2081-90. PubMed ID: 18955668
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 7. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.
    Cancer Res; 2004 Oct 01; 64(19):7099-109. PubMed ID: 15466206
    [Abstract] [Full Text] [Related]

  • 8. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    Jane EP, Premkumar DR, Pollack IF.
    J Pharmacol Exp Ther; 2006 Dec 01; 319(3):1070-80. PubMed ID: 16959960
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I, Pollak Y, Broneshter R, Iancu TC.
    FEBS J; 2011 Sep 01; 278(18):3494-507. PubMed ID: 21790999
    [Abstract] [Full Text] [Related]

  • 10. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
    Kramer BW, Götz R, Rapp UR.
    BMC Cancer; 2004 Jun 01; 4():24. PubMed ID: 15171791
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib.
    Hahn O, Stadler W.
    Curr Opin Oncol; 2006 Nov 01; 18(6):615-21. PubMed ID: 16988583
    [Abstract] [Full Text] [Related]

  • 12. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA, DeNicola GM, Winter SP, Tuveson DA.
    Mol Cell; 2009 Nov 13; 36(3):477-86. PubMed ID: 19917255
    [Abstract] [Full Text] [Related]

  • 13. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 13; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 14. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 15. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.
    J Hepatol; 2010 Jan 15; 52(1):79-87. PubMed ID: 19910069
    [Abstract] [Full Text] [Related]

  • 16. Raf pathway inhibitors in oncology.
    Bollag G, Freeman S, Lyons JF, Post LE.
    Curr Opin Investig Drugs; 2003 Dec 15; 4(12):1436-41. PubMed ID: 14763129
    [Abstract] [Full Text] [Related]

  • 17. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B.
    Oncologist; 2007 Apr 15; 12(4):426-37. PubMed ID: 17470685
    [Abstract] [Full Text] [Related]

  • 18. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.
    Lu X, Tang X, Guo W, Ren T, Zhao H.
    J Surg Oncol; 2010 Dec 01; 102(7):821-6. PubMed ID: 20812347
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
    Tong FK, Chow S, Hedley D.
    Cytometry B Clin Cytom; 2006 May 01; 70(3):107-14. PubMed ID: 16498671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.